Cellect Biotechnology And Canndoc Ltd. To Enter Into Strategic Pharma Grade Cannabis Commercial Deal For Reduction In Opioid Usage

vCellect Biotechnology Ltd. (NASDAQ:APOP), a developer of innovative technology that enables the functional selection of stem cells, today announced that its Board of Directors has approved, and the company has entered, subject to definitive agreements, into a commercial binding Letter Of Intent (LOI) with Canndoc Ltd, a leading pharma grade medical cannabis pioneer, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).